Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9
暂无分享,去创建一个
L. Kotra | I. Massova | M. Bernardo | R. Fridman | S. Mobashery | M. Tóth | I Massova | S Mobashery | M. Olson | D. Gervasi | M. Pietila | L P Kotra | R Fridman | M W Olson | D C Gervasi | M Toth | M M Bernardo | M Pietila | Martin Pietila
[1] R. Fridman,et al. Kinetic Analysis of the Binding of Human Matrix Metalloproteinase-2 and -9 to Tissue Inhibitor of Metalloproteinase (TIMP)-1 and TIMP-2* , 1997, The Journal of Biological Chemistry.
[2] Kenneth G. Mann,et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .
[3] R. Muschel,et al. Developmental expression of MMP‐9 (gelatinase B) mRNA in mouse embryos , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.
[4] M. Baumann,et al. Human gelatinase/type IV procollagenase is a regular plasma component , 1989, FEBS letters.
[5] W. Bode,et al. The C‐terminal (haemopexin‐like) domain structure of human gelatinase A (MMP2): structural implications for its function , 1996, FEBS letters.
[6] A. Strongin,et al. Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. , 1993, Kidney international.
[7] B C Finzel,et al. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity , 1998, Protein science : a publication of the Protein Society.
[8] U. Moll,et al. Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. , 1990, Cancer research.
[9] T. Ackermann. C. L. Brooks III, M. Karplus, B. M. Pettitt. Proteins: A Theoretical Perspective of Dynamics, Structure and Thermodynamics, Volume LXXI, in: Advances in Chemical Physics, John Wiley & Sons, New York 1988. 259 Seiten, Preis: US $ 65.25 , 1990 .
[10] J. Springer,et al. Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.
[11] G Murphy,et al. Tissue inhibitors of matrix metalloendopeptidases. , 1995, Methods in enzymology.
[12] G. González-Ávila,et al. Changes in Matrix Metalloproteinases during the Evolution of Interstitial Renal Fibrosis in a Rat Experimental Model , 1998, Pathobiology.
[13] J. Bousquet,et al. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. , 1997, American journal of respiratory cell and molecular biology.
[14] C. Walsh,et al. The behavior and significance of slow-binding enzyme inhibitors. , 2006, Advances in enzymology and related areas of molecular biology.
[15] M. Ågren,et al. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans , 1998, The British journal of surgery.
[16] H. Sengeløv,et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.
[17] A. Eisen,et al. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Karplus,et al. Proteins: A Theoretical Perspective of Dynamics, Structure, and Thermodynamics , 1988 .
[19] J. Enghild,et al. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.
[20] Y. Sun,et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.
[21] G. Fields,et al. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). , 1994, The Journal of biological chemistry.
[22] H. Tschesche,et al. A 25 kDa α2‐microglobulin‐related protein is a component of the 125 kDa form of human gelatinase , 1992, FEBS letters.
[23] R. Langer,et al. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing , 1996, Journal of cellular biochemistry.
[24] A. Eisen,et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. , 1989, The Journal of biological chemistry.
[25] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[26] A. Strongin,et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.
[27] P. V. von Hippel,et al. Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.
[28] J. Sipley,et al. Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.
[29] L. Liotta,et al. Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. , 1992, The Journal of biological chemistry.
[30] A. Koch,et al. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. , 1996, Arthritis and rheumatism.
[31] J. O'Connell,et al. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. , 1994, The Journal of biological chemistry.
[32] B. Glick,et al. A graphical method for extracting rate constants from some enzyme-catalyzed reactions not monitored to completion. , 1978, Canadian journal of biochemistry.
[33] W. Pearce,et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. , 1997, Surgery.
[34] R. Fridman,et al. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. , 1997, Cancer research.
[35] M. Maccoss,et al. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. , 1997, Journal of medicinal chemistry.
[36] T. Howard,et al. Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat , 1997, Hepatology.
[37] K. Shirato,et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. , 1997, American journal of respiratory cell and molecular biology.
[38] Gabriele Bergers,et al. MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.
[39] R. Fridman,et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.
[40] E. Lattman,et al. Crystal structure of the haemopexin-like C-terminal domain of gelatinase A , 1995, Nature Structural Biology.
[41] D. Gomez,et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.
[42] L. Liotta,et al. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. , 1990, Cancer research.
[43] C. López-Otín,et al. The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. , 1996, Journal of molecular biology.
[44] G Murphy,et al. A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.
[45] C. G. Knight. [2] Fluorimetric assays of proteolytic enzymes , 1995 .
[46] G. Murphy,et al. Gelatinases A and B. , 2002, Methods in enzymology.
[47] T. Thompson,et al. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. , 1998, The American journal of pathology.
[48] L. Kotra,et al. Matrix metalloproteinases: structures, evolution, and diversification , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] R. Muschel,et al. Metalloproteinases in tumor progression: the contribution of MMP-9. , 1994, Invasion & metastasis.
[50] Thiennu H. Vu,et al. Gelatinase B: Structure, Regulation, and Function , 1998 .
[51] C. Overall,et al. Specific, High Affinity Binding of Tissue Inhibitor of Metalloproteinases-4 (TIMP-4) to the COOH-terminal Hemopexin-like Domain of Human Gelatinase A , 1997, The Journal of Biological Chemistry.
[52] I. Campbell,et al. Solution structure of a type 2 module from fibronectin: implications for the structure and function of the gelatin-binding domain. , 1997, Structure.